Stock of the Day
September 24, 2020
Charles River Laboratories International (CRL)
$163.11
+$0.86 (+0.5%)
Market Cap:
$8.30B
About Charles River Laboratories International
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally.
It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Recent News
Charles River Laboratories International Q4 Earnings Transcript
(marketbeat.com)
Charles River Laboratories International, Inc. (NYSE:CRL) COO Birgit Girshick Acquires 1,514 Shares
(insidertrades.com)
Charles River Labs makes good on promise to reduce headcount
(bizjournals.com)
Charles River Laboratories International, Inc. (CRL) Q4 2024 Earnings Call Transcript
(seekingalpha.com)
Charles River Laboratories International, Inc. 2024 Q4 - Results - Earnings Call Presentation
(seekingalpha.com)
Charles River beats quarterly estimates on stable demand for drug development services
(reuters.com)
Charles River sees FY25 EPS $9.10-$9.60, consensus $9.60
(markets.businessinsider.com)
Charles River reports Q4 EPS $2.66, consensus $2.53
(markets.businessinsider.com)
Earnings To Watch: Charles River Laboratories (CRL) Reports Q4 Results Tomorrow
(msn.com)